KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Takeda Pharmaceutical (TAK) Equity Ratio (2018 - 2025)

Takeda Pharmaceutical (TAK) has 3 years of Equity Ratio data on record, last reported at 0.43 in Q1 2022.

  • For Q1 2022, Equity Ratio rose 7.56% year-over-year to 0.43; the TTM value through Mar 2025 reached 0.4, up 92.28%, while the annual FY2022 figure was 0.43, 7.56% up from the prior year.
  • Equity Ratio reached 0.43 in Q1 2022 per TAK's latest filing, up from 0.4 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.43 in Q1 2022 and bottomed at 0.38 in Q1 2019.
  • Average Equity Ratio over 3 years is 0.4, with a median of 0.4 recorded in 2021.
  • The widest YoY moves for Equity Ratio: up 7.56% in 2022, down 7.56% in 2022.
  • A 3-year view of Equity Ratio shows it stood at 0.38 in 2019, then rose by 6.72% to 0.4 in 2021, then grew by 7.56% to 0.43 in 2022.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.43 in Q1 2022, 0.4 in Q1 2021, and 0.38 in Q1 2019.